Dynavax: On Borrowed Time
(WorldNews Health)

Despite its sinking share price, Dynavax (DVAX) is not currently in extremis. However, it is in significant need of some wins over the near to mid term; in the absence of such wins, its future is bleak. This article will take readers on a row through the underworld of Dynavax`s performance since the FDA approval of its, so far, ill-fated Heplisav-B. We will also review prospects for positive catalysts that could right this listing vessel. Heplisav-B`s rollout has been tepid at best In the 10/18 posting, `Dynavax: Can Heplisav-B Carry The Load?`, I document Dynavax`s decade+ slog from 2006 on attempting to get FDA approval for its Hepatitis B vaccine which it calls Heplisav-B. This vaccine...